Podcasts about wegovy

What if every health issue is actually part of the same underlying problem? In this powerful episode of Mayim Bialik's Breakdown, Dr. Will Bulsiewicz — world-renowned gastroenterologist, gut health expert, and author of Plant Powered Plus — explains why your gut health is a story of your brain-gut connection. He shares why filling the ‘God-shaped hole' is a biological requirement to reduce inflammation and start to heal. Skin issues, bloating, autoimmune disease, chronic pain, fatigue, brain fog, and even bloating may all be hidden symptoms of inflammation, driven by modern life, chronic stress, poor sleep, trauma, disconnection, and most importantly, a lack of spiritual connection. Dr. B shares a startling personal story of his own spiritual awakening that he had previously been too self-conscious to share. Dr. Bulsiewicz also breaks down: - Why modern convenience keeps us stuck in fight-or-flight instead of rest & digest - Practical, science-backed ways to reduce inflammation - Why health protocols help, but are never one-size-fits-all - Why the colon is your first line of defense against inflammation - Top 3 ways we're destroying our gut microbiome - How GLP-1 drugs (Ozempic, Wegovy) are changing gut health, and their potential long-term risks - Importance of fiber, protein quality, diet variety, and why the Western diet fuels inflammation We also explore the powerful link between science, faith, and healing — why spirituality, purpose, and human connection measurably improve physical health, and how loneliness, trauma, and individualism damage the gut and immune system. Backed by science, we unpack how trauma causes digestive disease and why forgiveness can literally heal the body. Dr. Bulsiewicz shares his personal journey into spirituality, his emotional reconciliation with his father, and the remarkable experiences that followed his passing. If you've been struggling with unexplained symptoms, chronic inflammation, gut issues, fatigue, or are searching for a more whole-person approach to health, this episode may completely change how you think about healing. Dr. Will Bulsiewicz' new book, Plant Powered Plus: ⁠https://theguthealthmd.com/plantpoweredplus/⁠ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Are today's diabetes medications actually treating the disease, or just managing symptoms? In this episode, renowned diabetes educator Gary Scheiner breaks down the fast-growing world of GLP-1 drugs like Ozempic and Mounjaro – explaining what they do, who they're for, and why they're so effective… As the owner and clinical director of Integrated Diabetes Services, Gary has devoted his career to improving the lives of people with insulin-dependent diabetes. Living with type 1 diabetes since 1985, he is an award-winning Certified Diabetes Care and Education Specialist, a master's-level exercise physiologist, and was named 2014 Diabetes Educator of the Year by the American Association of Diabetes Educators. He's also the author of several foundational books, including Think Like a Pancreas, Get Control of Your Blood Sugar, and The Ultimate Guide to Accurate Carb Counting, and is a frequent speaker at national and international diabetes conferences. Jump in now to find out: The importance of finding a healthy balance when managing diabetes. What makes GLP-1 medications unique.  How diabetes impacts food digestion. What elevated glucose levels do to the rest of the body. To keep up with Gary and his work, follow him on LinkedIn!

What if every health issue is actually part of the same underlying problem? In this powerful episode of Mayim Bialik's Breakdown, Dr. Will Bulsiewicz — world-renowned gastroenterologist, gut health expert, and author of Plant Powered Plus — explains why your gut health is a story of your brain-gut connection. He shares why filling the ‘God-shaped hole' is a biological requirement to reduce inflammation and start to heal. Skin issues, bloating, autoimmune disease, chronic pain, fatigue, brain fog, and even bloating may all be hidden symptoms of inflammation, driven by modern life, chronic stress, poor sleep, trauma, disconnection, and most importantly, a lack of spiritual connection. Dr. B shares a startling personal story of his own spiritual awakening that he had previously been too self-conscious to share. Dr. Bulsiewicz also breaks down: - Why modern convenience keeps us stuck in fight-or-flight instead of rest & digest - Practical, science-backed ways to reduce inflammation - Why health protocols help, but are never one-size-fits-all - Why the colon is your first line of defense against inflammation - Top 3 ways we're destroying our gut microbiome - How GLP-1 drugs (Ozempic, Wegovy) are changing gut health, and their potential long-term risks - Importance of fiber, protein quality, diet variety, and why the Western diet fuels inflammation We also explore the powerful link between science, faith, and healing — why spirituality, purpose, and human connection measurably improve physical health, and how loneliness, trauma, and individualism damage the gut and immune system. Backed by science, we unpack how trauma causes digestive disease and why forgiveness can literally heal the body. Dr. Bulsiewicz shares his personal journey into spirituality, his emotional reconciliation with his father, and the remarkable experiences that followed his passing. If you've been struggling with unexplained symptoms, chronic inflammation, gut issues, fatigue, or are searching for a more whole-person approach to health, this episode may completely change how you think about healing. Try Notion, now with Notion Agent, at https://notion.com/break Dr. Will Bulsiewicz' new book, Plant Powered Plus: https://theguthealthmd.com/plantpoweredplus/ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this critical and timely episode, Dr. Cristina Castagnini is joined by Melainie Rogers, Founder and CEO of BALANCE Eating Disorder Treatment Center, to navigate the chaotic "wild west" of the current weight loss landscape. As GLP-1 medications like Ozempic and Wegovy saturate the market, Melainie pulls back the curtain on the alarming side effects that are often swept under the rug—from significant muscle atrophy to "medically induced anorexia." This conversation challenges the pervasive myth that thinness equals health, exposing how the lack of informed consent and the rise of med-spa prescriptions are setting the stage for a future of metabolic damage and disordered eating.SHOW NOTES: Click hereFollow me on Instagram: https://www.instagram.com/behind_the_bite Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textIn this episode, we open an honest, shame-free conversation about GLP-1 weight-loss medications like Ozempic, Wegovy, and Zepbound, and why choosing—or not choosing—medical support doesn't have to become a test of faith. Together, we explore the real questions many believers quietly carry: Am I taking a shortcut? Does this mean I don't trust God enough? We name the pressure, untangle medicine from morality, and remind listeners that wisdom and faith are not at odds. God is not keeping score, and health decisions don't need to be driven by fear, comparison, or guilt.We then walk through a practical four-step discernment process: asking with open hands, examining motives honestly, inviting wise counsel, and staying grounded in Scripture. Drawing from passages like Proverbs 3:5–6, James 1:5, Romans 12:2, Galatians 5:1, and Romans 8:1, we offer guidance for both those considering GLP-1s and those already using them—emphasizing ongoing renewal of the mind and closeness with Jesus so medication remains a tool, not a replacement for spiritual growth. You'll come away with reflection questions, helpful language for conversations with doctors and trusted leaders, and a renewed vision for health shaped by love, freedom, and wisdom. No matter your choice, the heart of change stays the same: Christ leads, shame has no authority, and God meets us as we listen.Class starts December 10thhttps://teamlifeisgood.com/goSupport the showLearn more about our Revelation Within Community: https://www.revelationwithin.org

Ozempic and other GLP-1 medications aren't just changing bodies. They're changing brains too. In this episode, I unpack what's really happening beneath the surface when you take medications like Ozempic, Wegovy, or Mounjaro. Not from a place of hype or fear-mongering, but from curiosity, neuroscience, and compassion. We talk about how GLP-1s influence hunger, motivation, emotional balance, and even your sense of self, and why so many people are surprised by the mental and emotional shifts that come along with physical weight loss. You'll learn: How GLP-1s interact with dopamine and reward pathways in the brain Why some people experience emotional blunting, reduced motivation, or changes in desire What actually happens when you stop taking them, and why hunger returning isn't failure, weakness, or a lack of discipline The neuroscience behind craving, self-control, and identity What hunger really does for emotional regulation and psychological resilience And just as important, this isn't an episode telling you what you should do. Whether a GLP-1 medication is right for you is a deeply personal decision, one that only you and your doctor can make together based on your body, your health history, and your life. There is no moral hierarchy here. Using a GLP-1 is not cheating, not taking shortcuts, and not something that requires justification or shame. This conversation is about understanding what these medications do to the brain so you can make informed, self-respecting choices, whatever those choices end up being. If this message resonates with you, like, comment, subscribe, and share to help more people understand how the brain and body really connect. ⚡️If you want to go deeper, Join my annual 21-Day Brain Detox Challenge: reset your mind, break toxic thought cycles, and build real mental resilience—$50 off + a FREE surprise gift from Dr. Leaf with code WELCOME50! Register here: https://21daybraindetox.com

Key Episode TakeawaysOral Wegovy is real, but it's not “just a pill version of the shot.” Absorption rules, dosing schedules, and patient selection matter a lot more than most headlines suggest.Switching from injections to oral GLP-1s requires a plan. The transition isn't one-size-fits-all, and dose timing, GI tolerance, and expectations need to be managed carefully.Weight regain after stopping GLP-1s is common, but not universal. SURMOUNT-4 data shows large variability, reinforcing that biology, not willpower, drives outcomes.Maintenance matters as much as weight loss. Some patients need continued therapy at lower doses, while others may maintain with lifestyle plus strategic medication use.Stopping abruptly is usually the worst approach. Gradual transitions and realistic long-term strategies reduce rebound weight gain.GLP-1s are chronic disease tools, not short-term fixes. Treating obesity like hypertension or diabetes leads to better outcomes and fewer surprises. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you're planning on taking a domestic flight soon, there are some things you need to know. Starting February 1, if you don't have a Real ID driver's license or another federally approved document like a passport, you'll need to pay a $45 fee at the airport to be able to get on your flight. This new fee was announced by TSA back in December. Guest: Carly Severn, KQED Until this year, drugs like Ozempic and Wegovy had been covered under Medi-Cal, California's Medicaid program. Now, the state says patients who only take these GLP-1 drugs for weight loss, are no longer covered. Reporter: Ana Ibarra, CalMatters Siskiyou County has reached a partial settlement in a class-action lawsuit alleging discrimination against Asian residents. Reporter: Justin Higginbottom, Jefferson Public Radio Learn more about your ad choices. Visit megaphone.fm/adchoices

Are GLP-1 medications truly revolutionizing medicine—or are we just seeing the latest healthcare hype cycle?In this part 1 of 2- part episode of Succeed In Medicine Podcast, Dr. Bradley Block sits down with Dr. Sean Wharton, to explore the real story behind GLP-1 agonists, how they were discovered, how they work, and why they suddenly became cultural blockbusters. Dr. Wharton explains that while the public sees these drugs as new, clinicians in diabetes care have been using them for over a decade. Originally developed to treat type 2 diabetes, GLP-1 medications revealed an unexpected benefit: meaningful weight loss. What began as a “sleeper drug” for glucose control became a global phenomenon once their impact on appetite and cravings was understood.A major theme of the discussion is the concept of “food noise”—the relentless mental pull toward food that many patients experience. Dr. Wharton describes how this biological drive makes long-term weight loss extraordinarily difficult and why willpower alone is rarely enough. GLP-1 medications work by quieting this food noise, helping patients regain control over their eating behaviors.The conversation also tackles tough questions clinicians and patients ask every day:Why do people need to stay on these medications long-term? Why do patients with diabetes lose less weight than those without? Is obesity truly a disease, and how should doctors talk about it? Are the benefits due to the drug itself or simply the weight loss? Dr. Wharton breaks down the biology of GLP-1 hormones, their role in insulin regulation and appetite control, and why these drugs have been such rare “unicorns” in medicine, highly effective with relatively few side effects.This episode sets the stage for Part 2, where they will dive deeper into myths, side effects, and practical prescribing guidance.Three Actionable TakeawaysObesity Is a Biological Disease, Not a Willpower Problem: Food noise and cravings are driven by hormones and brain chemistry. GLP-1 medications treat these biological mechanisms, not a character flaw.Long-Term Treatment Is Often Necessary: Just like medications for blood pressure or cholesterol, GLP-1 drugs address a chronic condition. Stopping treatment usually means the underlying biology—and weight—returns.Language Matters in Patient Care: Clinicians should approach weight with empathy and humility. Inviting patients into a respectful conversation about options is far more effective than blaming or shaming.About the Show:Succeed In Medicine covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the Guest:Dr. Sean Wharton holds doctorates in Pharmacy and Medicine from the University of Toronto. He is the Director of the Wharton Medical Clinic, a community-based weight management and diabetes clinic, and serves as Assistant Professor at the University of Toronto and Adjunct Professor at McMaster and York Universities.Dr. Wharton is the lead author of the 2020 Canadian Obesity Guidelines, recognized worldwide, and has published extensively in major medical journals including the New England Journal of Medicine. He is a passionate advocate for health equity and improving the way obesity is understood and treated in healthcare.LinkedIn: linkedin.com/in/drseanwhartonWebsite: whartonmedicalclinic.comAbout the Host:Dr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts Succeed In Medicine podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter  This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textIn this episode of On The Pen: The Weekly Dose, Dave Knapp breaks down why the idea of over-the-counter GLP-1 medications isn't radical speculation, it's a pattern already in motion. Drawing on FDA signals, past regulatory precedent with Orlistat, recent pricing negotiations, softened safety language, and public comments from pharmaceutical executives, Dave lays out the case that low-dose oral GLP-1s could be the first step toward OTC access. This episode connects the dots between regulation, access, pricing, and normalization of obesity treatment, and explains why the people laughing today may be asking how they missed it tomorrow.

The Food and Drug Administration on recently approved a pill version of Wegovy, Novo Nordisk's blockbuster weight loss drug. The Wegovy pill, as it's called, is first oral version of a GLP-1 drug that has been brought to market for weight loss. A second pill, from Eli Lilly, is also expected to be approved in the coming months. Nicolette M. Pace, a Registered Dietician, Chef, & Nutritionist, is here to talk about all this and more!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. We finally have the first-ever FDA-approved oral GLP-1 for treating obesity, and it's a much bigger deal than the headlines suggest…In this episode, I'm joined by Joseph Zucchi, PA, a clinical supervisor at a weight management clinic who lives and breathes the data behind obesity care. We break down oral Wegovy in practical terms: the real weight loss data, how it compares with weekly injections, why it's different from Rybelsus, and who it's best suited for. We also cover cost, insurance disruptions, and what to realistically expect if you're considering a switch.If you're trying to make sense of your options in a fast-changing landscape, whether due to coverage changes, injection concerns, or simple confusion — this conversation helps break it all down using real data.ReferencesConnect with Joseph Zucchi, PATransition Medic Medical Weight LossLinkedinAudio Stamps01:42 – Meet Joseph Zucchi, PA, clinical supervisor at a comprehensive weight management clinic with an on-site food store.04:35 – What is oral Wegovy and how does it compare to injectable semaglutide in terms of efficacy and weight loss?07:21 – The reformulation that makes oral Wegovy different from Rybelsus and why absorption matters.10:22 – How to take oral Wegovy correctly: timing, dosing instructions, and common mistakes to avoid.12:02 – Who should consider oral Wegovy and who might be better off sticking with injections?13:45 – Side effects, dosing transitions, and what to expect when switching from injectable to oral.22:03 – The importance of specialized care: why working with a weight management expert improves outcomes.24:00 – Pricing, insurance coverage challenges, and accessibility of oral Wegovy in 2026.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Send us a textShantanu Gaur, CEO of Allurion, returns to the podcast to break down their swallowable inflatable weight loss balloon, how it works, who it is for, how much it is expected to cost, and when patients can realistically expect access.We talk real world weight loss results, safety, availability in the US, and how Allurion fits into the broader obesity treatment conversation alongside GLP-1 medications and bariatric options.This is a clear, no hype discussion for patients who want more tools and better choices in obesity care.More Info:OTPLinks.com

his week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener mailbag questions that get to the heart of metabolic health. The team explains the real difference between meals and snacks, discusses whether GLP-1 medications can be appropriate for children in complex cases, explores why some people appear to be “non-responders” to Wegovy, and breaks down why alarming headlines about rapid weight regain miss the bigger metabolic picture. They also explain how to set a goal weight using body composition, labs, and overall health—rather than the scale alone.Key Questions Answered• What separates a meal from a snack metabolically?• Why can grazing all day backfire—even with healthy food?• Are GLP-1s ever appropriate for kids?• Why do some people feel hungrier as GLP-1 doses increase?• How are PCOS and insulin dysregulation connected?• What is a mixed meal tolerance test, and why does it matter?• Do GLP-1 users really regain weight faster?• How should goal weight be determined after major weight loss?Key Takeaways• Meals provide structure; snacks prevent long gaps—both matter.• GLP-1 “non-response” often signals deeper metabolic issues.• Weight regain reflects underlying dysfunction, not personal failure.• Maintenance dosing must be individualized.• Body composition matters more than BMI or scale weight.Dr. Cooper's Actionable Tips• Eat structured meals with carbs, protein, and fats.• Use snacks strategically to avoid long gaps.• Ask about deeper glucose/insulin testing when progress stalls.• Prioritize DEXA body composition over scale-based goals.• Avoid compounded GLP-1s—especially in children.Notable Quote“If you stop treating the metabolic dysfunction, the dysfunction is still there—and the body will drive weight back to where it was headed all along.”—Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Question: questions@fatsciencepodcast.comFat Science: No diets, no agendas—just science that makes you feel better. This podcast is for informational purposes only and is not intended to be medical advice.

The government is working on stopping busloads of people stripping rockpools of sea life in north Auckland; Pharmac is seeking clinical advice on whether the weight loss medication Wegovy should receive government funding. Donald Trump is doubling down on his efforts to acquire Greenland, threatening to slap tariffs on European allies standing in his way. The Black Caps have won the final ODI against India to take the series 2-1. The Government is considering lowering its housing intensification targets in Auckland after pushback from critics.

Pharmac is seeking clinical advice on whether the weight loss medication Wegovy should receive government funding. Professor of Paediatric Endocrinology at the University of Auckland, Wayne Cutfield spoke to Melissa Chan-Green.

Pharmac is seeking clinical advice on whether the weight loss medication Wegovy should receive government funding. Professor of Paediatric Endocrinology at the University of Auckland, Wayne Cutfield spoke to Melissa Chan-Green.

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why are investors buzzing about Novo Nordisk's Wegovy pill launch? And how has sentiment turned against software makers like Salesforce? Plus, what drove BlackRock's asset pile to a record $14 trillion? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them. Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Oprah Winfrey talked about her lifelong struggles with weight gain and yoyo dieting, and her GLP-1 journey. She insists she has an “obesity gene.” Health experts weigh in on her theory that obesity is predetermined by genetics. Spoiler: It has never been proven. “You don’t overeat and become obese; obesity causes you to overeat,” Oprah explained to the dimwits of “The View.” She’s framing obesity as a disease that must be treated, which is handy, seeing as she owns a minority stake in Weight Watchers, which now sells GLP-1s. Is Oprah selling surrender as science? Health and nutrition experts seem to think so. Wegovy now comes in a pill form, and the weightloss company is projected to make $1 billion over the next year. Also, shark attacks are making a comeback in Southern California. See omnystudio.com/listener for privacy information.

HEALTH NEWS   Probiotics emerge as a potent tool against depression and anxiety Altered microbiome: Oral bacteria play a role in chronic liver disease, study reveals Health issues linked to cosmetic jab complications From yoga to awe walks: Many paths lead to better mental health, largest analysis of well-being interventions finds Weight loss drugs may cause nutritional deficiencies without proper guidanc       Probiotics emerge as a potent tool against depression and anxiety University of Calgary (Canada), January 14 2026 (Natural News) For decades, the standard pharmaceutical approach to treating depression and anxiety has dominated treatment options, despite significant drawbacks including delayed effects, debilitating side effects and high relapse rates. Now, compelling new research is challenging this paradigm by pointing to a surprising source of relief: the gut. A comprehensive scientific analysis, synthesizing data from over 1,400 clinically diagnosed patients, reveals that probiotics—beneficial bacteria readily available as supplements—can produce substantial reductions in both depressive and anxious symptoms.   The analysis major findings include:     A major analysis of 23 clinical trials finds probiotics can significantly reduce symptoms of depression and anxiety in clinically diagnosed patients.   The benefits, appearing within 4-8 weeks, were comparable to some conventional antidepressants but without the same side-effect profile.   The gut-brain axis, a communication network largely ignored by conventional psychiatry, is central to understanding this connection.   Single-strain probiotic supplements, particularly certain Lactobacillus and Bifidobacterium species, showed the strongest mental health effects.   This research supports a holistic view of mental wellness, where gut health is a foundational component of treatment.     Altered microbiome: Oral bacteria play a role in chronic liver disease, study reveals Technical University Munich (Germany), January 15 2026 (Medical Xpress) Each year, more than two million people die from advanced chronic liver disease (ACLD). Previous research has linked gut microbiome disruptions to this condition and suggested that bacteria typically found in the mouth may colonize the gut. A new study published in Nature Microbiology now shows that identical bacterial strains occur in both the mouth and gut of patients with advanced chronic liver disease and also reveals a mechanism by which oral bacteria affect gut health. The researchers also found that this process coincides with worsening liver health. Researchers analyzed bacterial populations in saliva and stool samples from patients. The team found that both the gut and oral microbiome undergo significant changes as liver disease worsened, where changes to the oral microbiome were already detectable at earlier disease stages. In healthy individuals, bacterial communities differ substantially between body sites. In patients with liver disease, however, oral and gut microbiomes became increasingly similar as the disease progressed and nearly identical bacterial strains were recovered from the mouth and gut of patients. "These strains are typically found in the mouth and are rarely present in the healthy gut. However, we observed increases in the absolute abundances of these oral bacteria in patients with advanced chronic liver disease. This strongly suggests that these bacteria translocate from the mouth and colonize the gut," explains Melanie Schirmer, Professor of Translational Microbiome Data Integration at TUM.   Health issues linked to cosmetic jab complications Anglia Ruskin University (UK), January 9 2026 (Eurekalert)   Patients with chronic illnesses face a significantly higher risk of complications from cosmetic botulinum toxin injections, commonly known as Botox, according to a major UK study. Researchers from Anglia Ruskin University (ARU) surveyed 919 adults who had received botulinum toxin treatments for aesthetic reasons. The study, published in Aesthetic Surgery Journal, is the largest of its kind to have been carried out in the UK. Botulinum toxin injections are among the UK's most popular cosmetic procedures, with an estimated 900,000 treatments performed every year. Researchers found that underlying conditions such as type 1 diabetes, thyroid disorders, chronic migraine and skin disease dramatically increase the likelihood of adverse effects. According to the study, people with type 1 diabetes were 92 times more likely to experience nausea after treatment compared to those without the condition. Those with thyroid disorders and chronic migraine sufferers had an approximately 10-fold increase in the risk of nausea. Other complications associated with pre-existing conditions included headaches, bruising, muscle weakness and persistent eyelid droop (ptosis). Patients with cataracts were 30 times more likely to report headaches, and those with prior injuries had a 21-fold increased risk of losing facial expression.   From yoga to awe walks: Many paths lead to better mental health, largest analysis of well-being interventions finds Swansea University (UK), January 15 2026 (Medical Xpress) New research by Swansea experts has provided the largest ever comparison of well-being-focused interventions delivered to adults. The team reviewed 183 randomized controlled trials, representing almost 23,000 participants, and evaluated 12 categories of interventions ranging from psychological, physical, mind–body, and nature-based approaches to find out more. Their research was the first interdisciplinary comparison carried out across psychological, physical, mind-body and environmental interventions. The study gives an integrated view of how different disciplines contribute to well-being. By focusing on general adult samples rather than clinical groups, it provides evidence that will be relevant to developing public health, education, workplace well-being, and community programs. The researchers' key findings were: Most interventions improved well-being compared with inactive control groups; Strongest effects were found for combined exercise plus psychological interventions (for example, awe walks or meditation combined with walking); Mind–body interventions showed consistently moderate, reliable effects; Exercise alone produced similar benefits to many psychological interventions; and, Positive psychology interventions—both single-component and multicomponent—were also effective. The analysis shows that there is no single route to improving well-being. Mindfulness, compassion-based approaches, yoga, exercise and positive psychology interventions all showed moderate benefits compared with control groups, and combining physical activity with psychological interventions appeared particularly promising.   Weight loss drugs may cause nutritional deficiencies without proper guidance     University College London & Cambridge, January 7 2026 (News-Medical) People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge. In research published today in Obesity Reviews, the team found a lack of robust evidence surrounding nutritional advice and support and the impact this has on factors such as calorie intake, body composition, protein adequacy, and patient experiences. Weight loss drugs such as semaglutide and tirzepatide – available under brand names including Ozempic, Wegovy and Mounjaro – mimic the naturally-occurring hormone glucagon like peptide-1 (GLP-1), released into the blood in response to eating. The drugs suppress appetite, increase a feeling of being full, and reduce food cravings. These drugs can reduce calorie intake by between 16-39 %, making them a powerful tool to help people living with obesity and being overweight. However, there has been little research to examine their impact on diet quality, protein intake, or adequacy of micronutrients (vitamins and minerals). The researchers identified just 12 studies that looked at nutrition and diet alongside treatment with semaglutide or tirzepatide. Given the widespread – and increasing – use of these medications and the urgency of providing advice to individuals using the drugs, there was insufficient evidence from the studies to recommend strict low-fat diets to complement the weight loss drugs. Some observational studies found that people on the treatments often consumed excessive levels of total and saturated fat. These medications are transforming obesity care, but we know very little about how they shape people's daily lives, including changes in appetite, eating patterns, wellbeing, and quality of life.

Plus: U.K. regulators approve a higher dose of Wegovy. And FedEx secures financing ahead of the spin-off of its trucking division. Anthony Bansie hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Are GLP-1 weight loss drugs changing America—for better or worse? Michael explores the surprising ripple effects of drugs like Ozempic and Wegovy with PwC consumer markets leader Ali Furman. From gyms and grocery stores to travel, fashion, alcohol, gambling, and wellness, this conversation looks beyond weight loss to how these drugs may be reshaping consumer behavior, the economy, and even compulsive habits. Callers weigh in with real-world experiences that challenge assumptions about fitness, motivation, and what a “healthier society” really means. Original air date 15 January 2026. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Challenges of GLP-1 Drugs and New Dietary Guidelines for Americans. Nutritionist Leyla Muedin discusses the recent findings on weight regain after stopping GLP-1 receptor agonists like OZEMPIC and Wegovy, based on a recent British Medical Journal editorial. The episode also highlights the Dietary Guidelines for Americans (2025-2030), which recommend focusing on real, nutrient-dense foods, prioritizing protein, and reducing highly processed foods. Leyla addresses the importance of maintaining healthy eating habits during and after using GLP-1 drugs to achieve long-term weight management and overall health.

One way to make your money work for you while you’re sleeping is to invest in NFTs — take Merrill’s word for it! Glenn Beck of The Blaze has been using AI-generated podcasts during the overnight shift. Did his fans notice? If you're under a certain height, you won’t be allowed to enjoy Bad Bunny’s Super Bowl LX Halftime Show! Remember Quibi? It was the short-form streaming platform that lasted about five minutes. And now? We’re gifted with scripted micro dramas. Is your kid too fat? The obesity epidemic is causing us to get fatter younger, although GLP-1 weightloss meds like Ozempic and Wegovy seem to be helping adults. Now, kids may need to hop on the weightloss-shot gravy train. Processed foods and a sedentary lifestyle are to blame. The bald and the beautiful? It’s no longer a sad rite of passage when men lose their hair — it’s now considered a glow-up! Gen Z is now embracing the Mr. Sheen look. It’s called baldmaxxing and it means choosing to embrace hair loss rather than feeling ashamed.See omnystudio.com/listener for privacy information.

What if the explosion of GLP-1 drugs like Ozempic and Wegovy is not a weight loss revolution, but rather a warning sign that something in our metabolic health is fundamentally broken? Today, we take a deep dive into the lesser-known satiety hormones, such as CCK and PYY, exploring how dysfunction in these hormones could be silently accelerating your aging and sabotaging your health span. I'm excited to welcome Ashley Koff, a registered dietitian with more than 25 years of experience in functional and integrative nutrition, for a two-part series. In Part 1 today, we break down why your satiety hormones may be underperforming, how this links to aging and longevity, and simple strategies you can start using today to support metabolic health naturally. How to support your weight-health hormones: Focus on supporting your digestion first, rather than jumping straight into weight loss or metabolic fixes Ensure you're consuming enough protein and amino acids to support peptide hormone production Reduce gut irritants like alcohol, ultra-processed ingredients, and unnecessary fasting Nourish your body consistently, especially during times of hormonal change, instead of restricting View digestive symptoms as signs of dysfunction instead of problems to push through or ignore Bio: Ashley Koff Ashley Koff is a registered dietician and who is the founder of the Better Nutrition Program (BNP), the nutrition course director for UC Irvine's Susan Samueli Integrative Health Institute's Integrative and Functional Medicine Fellowship, and a faculty member at the Integrative and Functional Nutrition Academy (IFNA), where she teaches “An Integrative and Functional Nutrition Approach to Obesity and Weight Management.”  She is also the author of the upcoming book Your Best Shot (HarperOne, Jan. 6, 2026). A practitioner for more than 25 years, Koff is leading a transformative movement in personalized nutrition, turning “better, not perfect” choices into practical, sustainable strategies that deliver real health outcomes. Through patient stories and personal experience, she shows that optimal health is not just possible — it's essential to living your fullest life. Koff has been recognized as one of CNN's Top 100 Health Makers, featured in InStyle as “Hollywood's Leading Dietitian,” and selected as Westin's global nutrition ambassador.  In this episode: How separating weight from health leads to unhealthy behavior and long-term metabolic dysfunction Why a balanced approach is essential when using GLP-1 agonists and other interventions The importance of viewing digestive distress as an early warning sign, not a side effect to ignore How short-term diet “wins” can feel hopeful, yet fail to solve the underlying issue How metabolic health data points to a larger issue than most people realize The role weight-regulating hormones play beyond hunger and blood sugar Why supporting your weight health is foundational to your longevity  Links and Resources: Guest Social Media Links: Ashley Koff on Instagram  The Better Nutrition Program  Your Best Shot Relative Links for This Show:  ⁠⁠⁠⁠⁠Use Code FIBER to get 10% off GLP-1 Fiber ⁠⁠⁠⁠Use code CREATINE to get 10% off Creatine Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

If you're confused by weight loss medications like Ozempic or Wegovy, diet trends, or bariatric surgery options, you're not alone. In this episode of Baptist HealthTalk, Dr. Anthony Gonzalez, chief of surgery for Baptist Hospital of Miami and Medical Director of Bariatric Surgery at Baptist Health, sits down with Dr. Timothy Nowack, a general and bariatric surgeon, to separate fact from fiction and explain what actually works for long-term weight loss. They break down how GLP-1 weight loss medications work, who they're for, what kind of results are realistic, and why obesity is a chronic disease—not a personal failure. The conversation also explores when diet and lifestyle changes may be enough, when medications can help, and when weight loss surgery becomes an important option. If you're trying to make safe, informed decisions about your health without the hype, this episode provides clear, expert guidance. Watch now to learn which weight loss path may be right for you.Host:Anthony Gonzalez, M.D.Chief of Surgery, Baptist Hospital of Miami Medical Director of Bariatric Surgery, Baptist HealthGuest:Timothy Nowack, M.D.General SurgeonBaptist Health

Novo Nordisk CEO Mike Doustdar talks about launching a pill version of their blockbuster obesity drug Wegovy in the US. He speaks to Katie Greifeld in San Francisco at the annual JPMorgan Healthcare Conference. See omnystudio.com/listener for privacy information.

Audio roundup of selected biopharma industry content from Scrip over the business week ended January 9, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – oral Wegovy launches in the US; the biggest mid-cap catalysts in 2025; small cap pivots and zombie killers last year; commercial headwinds for last year's launches; and a look at Chinese firms' global Phase III activity. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ZV4GVVROYBEN7I6DQBOMQ3A3XE/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年1月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻—口服版Wegovy在美国上市； 2025年中盘股最大催化剂；去年小盘股转型与僵尸股清算；去年上市新药面临的商业逆风；以及中国企业全球三期临床动态。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ZV4GVVROYBEN7I6DQBOMQ3A3XE/ Playlist: on.soundcloud.com/gnr7PaOwflNKiAO7QX

Ever followed a million nutrition accounts, tried every “quick fix” in January, and still felt totally overwhelmed (and honestly…kinda hungry)? Girl, SAME.If you are tired of falling for detoxes, cleanses, fat-burning “miracles,” or just want real advice that actually fits into your busy, chaotic mom-life, today's episode is your new BFF. I brought on media dietitian and wellness myth-buster Abbey Sharp to spill the tea (literally) on how to actually lose weight mindfully AND keep it off without driving yourself absolutely nuts.We get into all the things you're Googling:Why protein, fiber, and healthy fats need to be your plate-building bestiesHow to make healthy eating actually doable (even with kids, work, NO time, and yes, rotisserie chicken from Costco!)The truth about SkinnyTok and all those wellness cult tips that make you feel like crapWhat's REALLY up with GLP-1 meds like Ozempic and the semaglutide craze—should you take it, when does it help, when does it get weird??Plus, Abbey shares her honest story…going from the “perfect” PhD track to totally switching careers and crushing the media game. Because life isn't about looking perfect; it's about finding your WHY and creating real, sustainable change.If you've ever wanted someone to break down nutrition for your REAL LIFE, help you shut down that diet noise, and remind you there's no one “right” way—we're here to help you find it!xoxo,JackieConnect with Abbey: 

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wondered what's really changing the game in weight loss treatments? Well, oral Wegovy might be it. Unlike other GLP-1 medications that require weekly injections, this is the first long-term weight-loss pill in its class. For many people, taking a daily tablet just feels way more doable—it's flexible, lowers mental barriers, and makes managing weight something that can actually fit into everyday life.In this episode, my guest is Joseph “Joe” Zucchi, a physician assistant and personal trainer with over a decade of experience in obesity medicine. He leads a multidisciplinary team in Salem, New Hampshire, helping patients achieve sustainable weight loss through a mix of fitness, nutrition, and medical care. Joe has been recognized for his work—leading his center to win awards, writing for outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity, and advocating for patient access to treatments like Zepbound. His insights make it clear that oral Wegovy isn't just another pill—it's part of a thoughtfully designed, patient-centered approach to obesity care.In this episode, we break down everything you need to know, including GLP-1 medications in simple terms, the future of oral Wegovy, what counts as success on the pill, side effects to expect, the technology behind it, how to take it properly, safely transitioning between pill and injection, who benefits most (and who should avoid it), and cost, coverage, and what to expect in 2026. If you've been curious about how oral Wegovy works and whether it could be right for you, this episode walks through it all in practical, real-world terms.Connect with Mr. Zucchi:Linkedin: Joseph Zucchi, PA-CX: JPZfitness Instagram: transitionweightlossConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Are you enjoying this? Are you not? Tell us what to do more of, and what you'd like to hear less of. The Reykjavík Grapevine's Iceland Roundup brings you the top news with a healthy dash of local views. In this episode, Grapevine publisher Jón Trausti Sigurðarson is joined by Heimildin journalist Aðalsteinn Kjartansson, Grapevine Editor-in-Chief Bart Cameron, and Grapevine friend and contributor Sindri Eldon to roundup the stories making headlines in recent weeks. On the docket this week are: Prime Minister Says She Can Work With Icelandic Populist PartyIn an interview with Heimildin this weekend, PM Kristrún Frostadóttir discussed many issues, but the attention grabbing issue was her statement that she could work with Miðflokkurinn (Center Party) on immigration issues.Greenland Discussion ContinuesIceland's Prime Minister, US. President and almost everybody else has done little but talk about Greenland during the past week. We try to catch up on that.Icelanders Are The Fattest Of The NordicsIn a survey conducted for 2024 and released last December, it turns out that Icelanders are the most overweight of all the Nordics. And out of the 80.000 Icelanders categorized as obese with a BMI over 30, more than 20.000, or 25% are taking GLP-1 drugs, such as Ozempic and Wegovy. We weigh in on the discussion.The US sizes a Tanker In Iceland's Exclusive Economic ZoneLast Wednesday, the US Navy apprehended an oil tanker, presumably on its way to Russia, within Iceland's Exlusive Economic Zone, but not within its territorial waters. Icelanders Won't Be Required To Undergo Medical Exam To Renew Drivers License Until They Turn 75A new law has been proposed by the People's Party to move a required medical exam for renewing Icelandic driver licenses from 70 years old to 75 years old. The Icelandic Word Of The Year Is Paid Parking (i. Gjaldskylda)We discuss the annual choice of “word of the year” in Iceland, which this time around was the word Gjaldskylda, or paid parking, which has led to numerous misunderstandings on social media.Support the show------------------------------------------------------------------------------------------SHOW SUPPORTSupport the Grapevine's reporting by becoming a member of our High Five Club: https://grapevine.is/high-five-club/Or donate to the Grapevine here:https://support.grapevine.isYou can also support the Grapevine by shopping in our online store:https://shop.grapevine.is------------------------------------------------------------------------------------------ This is a Reykjavík Grapevine podcast.The Reykjavík Grapevine is a free alternative magazine in English published 18 times per year, biweekly during the spring and summer, and monthly during the autumn and winter. The magazine covers everything Iceland-related, with a special focus culture, music, food and travel. The Reykjavík Grapevine's goal is to serve as a trustworthy and reliable source of information for those living in Iceland, visiting Iceland or interested in Iceland. Thanks to our dedicated readership and excellent distribution network, the Reykjavík Grapevine is Iceland's most read English-language publication. You may not agree with what we write or publish, but at least it's not sponsored content.www.grapevine.is

In this important episode, I break down the newly FDA-approved Wegovy pill and what it means for obesity treatment. The first oral GLP-1 medication for obesity has arrived, offering a needle-free alternative to weekly injections. This development could transform access for patients who've avoided treatment due to injection hesitation, cost barriers, or preference for daily pill routines. Tune in to learn what the Wegovy pill is, how it works, and why it represents a major step forward in giving patients more options for sustainable weight loss. Sign up for the Back on Track: Setting the Vision for your health Masterclass:  https://drshellymd.kit.com/ecc62a0638   Episode Highlights: How the Wegovy pill works as a daily medication vs. weekly injections The science behind GLP-1 receptor agonists and appetite regulation Clinical data showing approximately 13.6% body weight reduction Overcoming injection hesitation—a major barrier to treatment adherence Proper dosing: daily pill on empty stomach with specific timing requirements Common side effects and important black box warnings to know Affordable self-pay pricing: starting at $149/month through NovoCare pharmacy program Why more options mean better care for chronic disease management   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

NSW Police Inspector Amy Scott, the heroic police officer who confronted and killed the Westfield Bondi Junction attacker has been diagnosed with cancer; A Victorian bushfire appeal has been launched, with premier Jacinta Allan calling for public donations to support affected communities; Australians could soon get cheaper access to the popular weight-loss drug Wegovy, with the federal government set to add the medication to the Pharmaceutical Benefits Scheme; and Hollywood's finest celebrate the 83rd Golden Globes. THE END BITS Support independent women's media Check out The Quicky Instagram here GET IN TOUCHShare your story, feedback, or dilemma! Send us a voice note or email us at thequicky@mamamia.com.au CREDITS Host: Ailish Delaney Audio Producer: Lu Hill Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Nếu được đưa vào PBS, Wegovy - một loại thuốc tiêm chứa hoạt chất semaglutide, tương tự Ozempic - có thể giúp hàng trăm ngàn người Úc giảm đáng kể chi phí điều trị, hiện đã lên tới 4,000-5,000 đô la mỗi năm.

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to discuss a study that looks at the correlation between caffeine intake and the risk for diabetes, the new federal dietary guidelines, and how the Wegovy pill is different from the injection. He also talks about the most important heart health habit […]

El presidente Trump se reunió con ejecutivos de las grandes petroleras estadounidenses para alcanzar un acuerdo de 100 mil millones de dólares para reactivar la explotación de petróleo en Venezuela.En otras noticias: Se dieron a conocer las imágenes tomadas desde el celular del agente Jonathan Ross del intercambio verbal con Renee Good minutos antes de dispararle mortalmente.El alcalde de Minneapolis exige una "investigación justa" y pide que se incluya a expertos locales dentro de la invesrtigación.Se conocen nuevos detalles de las razones por las que Renee Good se enfrentó con los agentes, la mujer estaba actuando como observadora de los operativos migratorios para alertar a la comunidad inmigrante.En Portland otro agente de migración abrió fuego contra una pareja venezolana frente a un hospital. La comunidad está molesta y se ha manifestado en contra. 

Plus: Andreessen Horowitz raises over $15 billion across several funds. And LG Electronics expects to post a quarterly operating loss for the first time since 2016. Julie Chang hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber led off the show with market reaction to the December employment report: Non-farm jobs growth came in lower than expected, up 50,000. The unemployment rate fell to 4.4%. National Economic Council Director Kevin Hassett joined the program with White House reaction to the results. The anchors and Hassett discussed him being in the running for Fed chair, the Supreme Court's upcoming decision on tariffs and what to expect from President Trump's Friday meeting with oil CEOs about reviving production in Venezuela. Also in focus: The stocks surging on Meta's nuclear deals, Amazon's pharmacy to offer Novo Nordisk's Wegovy pill.Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The first highly effective oral GLP-1 weight loss medication is here. In this episode, Lisa Oldson, MD breaks down the FDA-approved PILL version of semaglutide (oral Wegovy), how GLP-1 receptor agonists work for weight loss, expected results, side effects, cost, and who qualifies for these medications. She also discusses why weight loss medication is not “cheating,” how GLP-1 oral meds compare to injectables, and the World Health Organization's new recommendations supporting long-term use of GLP-1 medications for excess weight. If you're curious about GLP-1 weight loss pills, obesity treatment, and evidence-based approaches to long-term health, this episode is for you.You'll learn:What's new about ORAL (pill form) WegovyWhy weight loss medication is not cheatingHow the brain regulates weightHow GLP-1 medications workMedication + lifestyle: not either / orThanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

January 8, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Trump administration releases new dietary guidelines backed by HHS Secretary RFK Jr., recommending avoidance of ultra-processed foods and added sugars while endorsing red meat and full-fat dairy Eli Health unveils instant saliva-based tests for testosterone and progesterone at $8 per test, with results in minutes and Q1 rollout ahead Mark Mastrov and LongRange Capital reacquire 24 Hour Fitness, with plans to upgrade clubs for strength and recovery while preparing for international growth Smart ring shipments jumped 50% in 2025, outpacing smartwatches as Oura explores digital IDs and payments beyond health tracking Novo Nordisk's Wegovy pill launches nationwide as first oral GLP-1 for weight loss at $149/month through pharmacies and telehealth providers More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

Studies suggest that once you stop taking wegovy, you could gain the weight you lost back. Open AI is launching Chat GPT Health. New US dietary guidelines change the alcohol guidelines.See omnystudio.com/listener for privacy information.

Studies show that more you spend on your wedding, the more likely you are to get a divorce. Fred and the crew discuss! And Wegovy users are having a hard time keeping weight off after they stop using... Listen now!See omnystudio.com/listener for privacy information.

Seattle is desperately trying to backtrack after reports it was moving towards drug decriminalization. Just like Minnesota, Washington is dealing with its own allegations of fraud. There’s now a pill version of the popular weight loss drug Wegovy. // LongForm: GUEST: Let's Go Washington's Brian Heywood on what's next now that two citizen intitiatives have received enough signatures to make it on the ballot. // Quick Hit: An update on allegations that Hilton hotels were denying reservations to ICE agents.

(January 07, 2025) A report by U-Haul shows California recorded the largest exodus of do-it-yourself movers of any state in 2025. KFI reporter Heather Brooker joins the show from a neighborhood in Altadena where the rebuilding has started. Dr. Jim Keany, Chief Medical Officer at Dignity Health St. Mary Medical Center in Long Beach, joins The Bill Handel Show for 'Medical News'! Dr. Keany talks with Bill about the CDC slashing vaccine recommendations for kids, flu reaching the highest levels in the U.S. in 25 years, and Wegovy now in pill form.See omnystudio.com/listener for privacy information.

 President Trump rallies the House GOP as midterms ratchet up, minimum wage hikes up in several states, and Wegovy ditches the needle. Get the facts first with Evening Wire. - - - Ep. 2566 - - - Wake up with new Morning Wire merch: https://bit.ly/4lIubt3 - - - Privacy Policy: https://www.dailywire.com/privacy morning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices

US to ‘run' Venezuela after Maduro taken into custody: Trump; Wegovy pill becomes available to consumers; Napheesa Collier talks injury, season 2 of 'Unrivaled' Learn more about your ad choices. Visit podcastchoices.com/adchoices

If society privileges "thin" people, should you aspire to conform? And at what cost?Last year, online influencer Slim Kim went viral for a TikTok where she said she loves "being skinny." It sparked a debate that continued throughout 2025: how do we talk about bodies without falling into "body fascism." And with drugs like Ozempic and Wegovy flooding the market, how are the ways we talk about bodies shifting and changing?Brittany is joined by authors Emma Specter and Kate Manne to find out: what's so wrong with loving being skinny?This episode originally aired on December 6, 2024.Support Public Media. Join NPR Plus.Follow Brittany Luse on Instagram: @bmluseFor handpicked podcast recommendations every week, subscribe to NPR's Pod Club newsletter at npr.org/podclub.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy